Through the acquisition of the Aarhus-based biotech company NeuronIcon, Lundbeck will gain ownership of technologies that may lead to a breakthrough in the treatment of brain damage following strokes or similar events. The acquisition is the result of Lundbeck's intensified collaboration with universities in Denmark and abroad.

Several area health care organizations agree that today's tough economic times can make staying healthy a challenge. The organizations provided tips for Ohioans to stay healthy. Those organizations are: The Athletic Club of Columbus, Central Ohio Diabetes Association, Columbus Dietetic Association, Lilly USA, Mental Health America of Franklin County, NAMI Ohio, Ohio Association of Free Clinics, Ohio Department of Health and Prevent Blindness Ohio.

Roche announced that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study.

GlaxoSmithKline plc (GSK) has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m).

H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD).

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.

Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.